NeurAxis, Inc.

NRXS

AMEXHealthcareBiotechnology

Open in GoAI

Previous close

$6.15

−$0.12 · -1.91%

Aug 21, 4:00 PM ET

Pre-market

$6.16

+$0.01 · +0.16%

Aug 24, 4:44 AM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

47/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Undervalued

Momentum

Neutral

Sentiment

Mixed

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Brian Carrico
Listed since: Aug 9, 2023
Employees: 24

Market position

Day range

Current $6.15

$6.15$6.34

52-week range

Current $6.15

$2.21$9.33

Open: $6.27
Previous close: $6.27
Volume: 95.89K; 0.76× average
Average volume: 126K; Average daily volume
Market cap: 76.74M USD
Beta: 1.48; Market reference 1
50-day average: $6.7832; -9.33% below average
200-day average: $5.7747; +6.50% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM): -7.99×
P/B (TTM): 11.07×
P/S (TTM): 14.43×
Dividend yield: 0.00%

Profitability & efficiency

Gross margin: 85.56%
Operating margin: -144.51%
Net margin: -148.04%

Financial health

Debt / equity: 0.04×

NRXS news

zacks.comAug 14, 2026

NRXS Stock Dips Post Q2 Earnings Despite Revenue Surge, Gross Margin Up

NeurAxis delivers record second-quarter 2026 revenues as stronger IB-Stim demand, higher pricing and an improved reimbursement mix lift gross margin.

Read source

seekingalpha.comAug 11, 2026

NeurAxis, Inc. (NRXS) Q2 2026 Earnings Call Transcript

Read source

globenewswire.comAug 4, 2026

NeurAxis Expands Payer Coverage with New Policies

CARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating…

Read source

globenewswire.comJul 28, 2026

NeurAxis to Host Second Quarter 2026 Results and Business Update Call on Tuesday, August 11, 2026

CARMEL, Ind., July 28, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and…

Read source